查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1718266

核酸藥物市場按藥物類型、分子類型、給藥途徑、治療領域和最終用戶分類－2025-2030 年全球預測

Nucleic Acid-Based Drugs Market by Drug Type, Molecule Type, Route of Administration, Therapeutic Area, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

核酸類藥物市場規模預計2024年將達333.7億美元，2025年將達377.6億美元，2030年將達709.5億美元，複合年成長率為13.39%。

主要市場統計數據
基準年2024年 333.7億美元
預計2025年 377.6億美元
預測年份 2030 709.5億美元
複合年成長率（%） 13.39%

過去十年來，由於科學突破、創新臨床策略以及對分子生物學的深入了解，核酸藥物周圍的環境發生了巨大變化。這個市場已經從一個小眾研究領域轉變為一個充滿活力的行業，正在重新定義複雜疾病的治療性介入。基因表現調控的開創性發現影響了各種類型藥物的發現和開發，包括針對 RNA 和 DNA 功能的藥物，提供了前所未有的治療可能性。新穎的遞送機制、增強的合成技術和強力的監管支持的整合進一步確立了該領域作為未來治療方法基石的地位。

生物技術與數位技術的日益融合不僅加速了研究，而且為快速的臨床應用鋪平了道路。學術界、製藥公司和臨床研究機構的相關人員正在利用這些發展來解決未滿足的醫療需求。透過突破性科學和創新技術的結合，該市場有望顯著改善患者的治療效果和治療的精確度。因此，核酸藥物市場的持續發展反映出一個強大且有彈性的生態系統，能夠在快速變化的全球醫療保健環境中克服挑戰並抓住機會。

核酸藥物市場的變革

近年來，核酸藥物市場正在發生變革，重新定義治療方法和市場動態。臨床試驗活動的激增凸顯了精準醫療的重要性，使得早期化合物能夠更快地通過臨床流程。輸送系統的突破性創新顯著提高了核酸療法的生物有效性和靶向功效，減輕了與穩定性和細胞攝取相關的傳統挑戰。

基因組編輯的進步，加上對 RNA 生物學的深入了解，為多功能、特異性患者的下一代治療方法提供了框架。新的經營模式和協作框架促成了跨部門夥伴關係，學術界、研究界和工業界的領導者共用見解和資源。這種合作對於將候選藥物納入簡化的監管途徑並加速其進入市場至關重要。

這種轉變的影響是深遠的，不僅加速了市場成長，也刺激了推動技術創新的投資浪潮。透過增強的運算建模和尖端生物製造技術，相關人員現在可以在藥物開發中享有更大的靈活性、設計精度和業務效率。市場中的這種變革性轉變正在創造一種環境，在這種環境中，持續改進和突破性研究是長期成功的基礎。

推動策略發展的關鍵環節分析

核酸藥物市場的多面性透過多樣化的細分策略凸顯出來，這些策略為潛在趨勢提供了關鍵見解。就藥物類型而言，市場涵蓋一系列治療方式，包括反義寡核苷酸、DNA/RNA適體、基於mRNA的治療劑、核苷類似物和RNA干擾（RNAi）治療劑。我們對 RNAi 療法進行了更深入的研究，將其分為微型RNA(MiRNA)、短髮夾 RNA (ShRNA) 和短干擾 RNA (SiRNA)。

此外，基於分子類型的細分將市場分為大分子和小分子，每個部分都表現出自己的市場動態和商業性潛力。按給藥途徑細分可提供對患者依從性和結果的寶貴見解，方式包括吸入和肌肉注射到靜脈注射、口服和皮下注射，反映了患者需求和臨床實踐的複雜性。

在治療領域方面，市場分析涵蓋以下治療領域：心血管疾病、感染疾病、代謝疾病、神經系統疾病、腫瘤學和罕見疾病。感染疾病分為感染疾病、感染疾病感染和病毒感染疾病，腫瘤分為骨髓惡性腫瘤和固態腫瘤。市場區隔評估對學術和研究機構、合約研究組織、醫院和研究組織以及製藥和生物技術公司的影響。這種細粒度的細分不僅為戰略決策提供資訊，而且還提供了有關患者人口統計、治療方法類型和區域差異如何共同塑造市場軌蹟的詳細視圖。

目錄

第1章 引言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 遺傳疾病和慢性疾病的發生率不斷上升，推動了對核酸藥物的需求。
      • 擴大政府投入，推動核酸藥物生產
    • 限制因素
      • 核酸藥物的製造和配方成本高昂
    • 機會
      • 透過生技公司之間的夥伴關係加強核酸藥物
      • 開發下一代遞送系統以提高核酸藥物的生物有效性
    • 任務
      • 對核酸藥物安全性和輸送效率的擔憂
  • 市場區隔分析
    • 藥物類型：基於 mRNA 的療法因其在疫苗開發中的變革性影響以及在重大健康危機期間的快速治療反應而得到應用
    • 分子類型：小分子藥物因其在製造、給藥和成本效益方面的優勢而被廣泛採用。
    • 給藥途徑：肌肉注射因在疫苗研發中發揮重要作用而較為普遍。
    • 治療領域：腫瘤核酸藥物
    • 最終用戶：由於需要先進的工具來解開基因調控和表達的複雜性，因此廣泛應用於學術和研究實驗室。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社會
    • 技術的
    • 合法的
    • 環境

6. 核酸藥物市場（依藥物類型）

  • 反義寡核苷酸
  • DNA/RNA適體
  • 基於mRNA的療法
  • 核苷類似物
  • RNA干擾（RNAi）療法
    • 微型RNA（MiRNA）
    • 短髮夾RNA（ShRNA）
    • 小干擾RNA（SiRNA）

7. 核酸藥物市場（依分子類型）

  • 大分子
  • 小分子

8. 核酸藥物市場（依給藥途徑）

  • 吸入
  • 肌肉注射
  • 靜脈
  • 口服
  • 皮下

9. 核酸藥物市場（依治療領域）

  • 心血管疾病
  • 感染疾病
    • 細菌感染疾病
    • 黴菌感染疾病
    • 病毒感染
  • 代謝紊亂
  • 神經系統疾病
  • 腫瘤學
    • 造血系統惡性腫瘤
    • 固態腫瘤
  • 罕見疾病

第 10 章核酸藥物市場（依最終使用者）

  • 學術研究所
  • 合約研究組織
  • 醫院和診所
  • 製藥和生物技術公司

11.美洲核酸藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

12. 亞太地區核酸藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

13. 歐洲、中東和非洲核酸藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭情境分析
  • 戰略分析與建議

公司名單

  • Alnylam Pharmaceuticals, Inc.
  • Amgen Inc.
  • Arcturus Therapeutics Holdings Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Beam Therapeutics Inc.
  • Biogen, Inc.
  • BioMarin Pharmaceutical Inc.
  • BioNTech SE
  • Bluebird Bio, Inc.
  • CRISPR Therapeutics AG
  • CureVac NV
  • Dynavax Technologies Corporation
  • Editas Medicine, Inc.
  • Eli Lilly and Company
  • Evotec SE
  • F. Hoffmann-La Roche Ltd.
  • Generation Bio Co.
  • Gilead Sciences, Inc.
  • GSK PLC
  • Intellia Therapeutics, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Orna Therapeutics, Inc.
  • Pfizer Inc.
  • ProQR Therapeutics NV
  • Sangamo Therapeutics, Inc.
  • Sanofi SA
  • Sarepta Therapeutics, Inc.
  • Silence Therapeutics PLC
  • Stoke Therapeutics, Inc.
  • Takeda Pharmaceutical Company Limited
  • Vertex Pharmaceuticals Incorporated
  • Voyager Therapeutics, Inc.
  • Wave Life Sciences Ltd.
Product Code: MRR-CA7E340319CE

The Nucleic Acid-Based Drugs Market was valued at USD 33.37 billion in 2024 and is projected to grow to USD 37.76 billion in 2025, with a CAGR of 13.39%, reaching USD 70.95 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 33.37 billion
Estimated Year [2025] USD 37.76 billion
Forecast Year [2030] USD 70.95 billion
CAGR (%) 13.39%

The landscape of nucleic acid-based drugs has evolved substantially over the past decade, driven by significant scientific breakthroughs, innovative clinical strategies, and a deepening understanding of molecular biology. This market has transformed from a niche area of research to a dynamic field that is redefining therapeutic interventions for complex diseases. Pioneering discoveries in gene expression modulation have shaped the discovery and development of various drug types, such as those that target RNA and DNA functionality, leading to unprecedented therapeutic possibilities. The integration of novel delivery mechanisms, enhanced synthesis techniques, and robust regulatory support has further established this sector as a cornerstone for future medical treatments.

The ongoing convergence of biotechnology and digital advancements has not only accelerated research but has also paved the way for rapid clinical translations. Stakeholders across academia, pharmaceutical companies, and clinical research institutes are leveraging these developments to address unmet medical needs. This blend of breakthrough science and innovative technology positions the market to deliver substantial improvements in patient outcomes and therapeutic precision. As such, the ongoing evolution of the nucleic acid-based drugs market reflects a robust and resilient ecosystem capable of surmounting challenges and seizing opportunities in a rapidly changing global healthcare environment.

Transformative Shifts in the Nucleic Acid-Based Drugs Market

Recent years have witnessed transformative shifts in the nucleic acid-based drugs market that are redefining therapeutic modalities and market dynamics. A surge in clinical trial activity has underscored the importance of precision medicine, leading to early-stage compounds progressing more rapidly through clinical pipelines. Breakthrough innovations in delivery systems have significantly improved the bioavailability and targeting efficacy of nucleic acid therapeutics, thereby mitigating traditional challenges associated with stability and cellular uptake.

Advances in genomic editing, coupled with an enhanced understanding of RNA biology, have provided the framework for next-generation treatments that are both versatile and patient-specific. Emerging business models and collaborative frameworks have enabled cross-sector partnerships, where academia, research organizations, and industry leaders share insights and resources. This collaborative spirit has been essential in integrating novel drug candidates into streamlined regulatory pathways and expedited market accesses.

The impact of these shifts is far-reaching, inspiring a wave of investments that not only accelerate market growth but also foster technological innovation. With enhanced computational modeling and state-of-the-art biomanufacturing techniques, stakeholders now enjoy greater flexibility, design precision, and operational efficiency in drug development. The transformative shifts in this market are creating an environment where continuous improvement and breakthrough research are the foundations for long-term success.

Key Segmentation Insights Driving Strategy

The multifaceted nature of the nucleic acid-based drugs market is highlighted by a diverse segmentation strategy that provides critical insights into underlying trends. From a drug type perspective, the market encompasses an array of therapeutic modalities including Antisense Oligonucleotides, DNA/RNA Aptamers, mRNA-Based Therapeutics, Nucleoside Analogs, and RNA Interference (RNAi) Therapeutics. In particular, RNAi Therapeutics are examined in greater depth by further classifying the category into MicroRNA (MiRNA), Short Hairpin RNA (ShRNA), and Short Interfering RNA (SiRNA), each with distinctive mechanisms of action that pave the way for targeted therapy solutions.

In addition, the segmentation based on molecule type divides the market into Large Molecules and Small Molecules, with each segment demonstrating unique market dynamics and commercial potentials. The route of administration segmentation provides valuable insights into patient compliance and therapeutic outcomes, with modalities ranging from Inhalation and Intramuscular to Intravenous, Oral, and Subcutaneous methods that reflect the complexity of patient needs and clinical practices.

Examining therapeutic areas, the market is analyzed across Cardiovascular Diseases, Infectious Diseases, Metabolic Disorders, Neurological Disorders, Oncology, and Rare Diseases. Further refinement in this area sees the Infectious Diseases category dissected into Bacterial Infections, Fungal Infections, and Viral Infections, while Oncology is analyzed through the lens of Hematologic Malignancies and Solid Tumors. Complementing this, market end-user segmentation evaluates the impact on Academic & Research Institutes, Contract Research Organizations, Hospitals & Clinics, and Pharmaceutical & Biotechnology Companies. This intricate segmentation not only informs strategic decision-making, but also provides a granular view of how patient demographics, therapy types, and regional variations coalesce to shape market trajectory.

Based on Drug Type, market is studied across Antisense Oligonucleotides, DNA/RNA Aptamers, mRNA-Based Therapeutics, Nucleoside Analogs, and RNA Interference (RNAi) Therapeutics. The RNA Interference (RNAi) Therapeutics is further studied across MicroRNA (MiRNA), Short Hairpin RNA (ShRNA), and Short Interfering RNA (SiRNA).

Based on Molecule Type, market is studied across Large Molecule and Small Molecule.

Based on Route of Administration, market is studied across Inhalation, Intramuscular, Intravenous, Oral, and Subcutaneous.

Based on Therapeutic Area, market is studied across Cardiovascular Diseases, Infectious Diseases, Metabolic Disorders, Neurological Disorders, Oncology, and Rare Diseases. The Infectious Diseases is further studied across Bacterial Infections, Fungal Infections, and Viral Infections. The Oncology is further studied across Hematologic Malignancies and Solid Tumors.

Based on End-User, market is studied across Academic & Research Institutes, Contract Research Organizations, Hospitals & Clinics, and Pharmaceutical & Biotechnology Companies.

Global Regional Dynamics in Nucleic Acid-Based Drugs

Assessing the regional landscape of the nucleic acid-based drugs market provides a comprehensive perspective on global trends and regional variances. Market trends in the Americas continue to be driven by robust regulatory frameworks and extensive research infrastructure, attracting substantial investments and fostering innovation across both established markets and emerging clusters. Collaborative ecosystems with world-class research institutions and commercial players further strengthen market resilience.

In regions encompassing Europe, the Middle East & Africa, a blend of progressive regulatory reforms and increasing clinical trial activities is contributing to market expansion. This region is characterized by a harmonious blend of advanced research capabilities and strategic governmental incentives, thereby facilitating rapid clinical translations and enabling a smooth integration of breakthrough therapies into therapeutic regimens.

Meanwhile, in the Asia-Pacific region, rapid industrialization, rising healthcare demands, and a surge in technological advancements are collectively igniting market growth. Investments in infrastructure coupled with a rising focus on personalized medicine have catalyzed the development of state-of-the-art genome therapies. Each of these regions plays a significant role in influencing market strategies and expanding the global footprint of nucleic acid-based therapies, reflecting both localized opportunities and broader industry trends.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Strategic Company Performances and Market Leadership

In a rapidly advancing field marked by innovation and evolving therapeutic approaches, key companies have emerged as market leaders and principal drivers of growth. Prominent organizations such as Alnylam Pharmaceuticals, Inc., Amgen Inc., and Arcturus Therapeutics Holdings Inc. have spearheaded research initiatives that underscore the clinical potential of nucleic acid-based interventions. Moreover, companies like Arrowhead Pharmaceuticals, Inc. and AstraZeneca PLC have positioned themselves at the forefront of strategic collaborations and clinical advancements, further cementing their roles as industry pioneers.

The market is also notably influenced by dynamic contributions from Beam Therapeutics Inc. alongside acclaimed biopharmaceutical enterprises including Biogen, Inc. and BioMarin Pharmaceutical Inc. Furthermore, innovative players such as BioNTech SE and Bluebird Bio, Inc. are continually making strides through novel therapeutic platforms and breakthrough research. The involvement of CRISPR Therapeutics AG, CureVac N.V., and Dynavax Technologies Corporation underscores the commitment to harnessing genetic engineering techniques for therapeutic advancements.

Advancements spearheaded by Editas Medicine, Inc., Eli Lilly and Company, and Evotec SE have been pivotal in transforming market rifts into opportunities, while Generation Bio Co., Gilead Sciences, Inc., and GSK PLC continue to drive clinical research forward. With strategic insights from Intellia Therapeutics, Inc., Ionis Pharmaceuticals, Inc., and Merck & Co., Inc., along with innovative contributions by Moderna, Inc., Novartis AG, Novo Nordisk A/S, Orna Therapeutics, Inc., and Pfizer Inc., the competitive landscape remains both robust and dynamic. The involvement of additional influential organizations such as ProQR Therapeutics N.V., Sangamo Therapeutics, Inc., Sanofi SA, Sarepta Therapeutics, Inc., Silence Therapeutics PLC, Stoke Therapeutics, Inc., Takeda Pharmaceutical Company Limited, Vertex Pharmaceuticals Incorporated, Voyager Therapeutics, Inc., and Wave Life Sciences Ltd. further exemplifies the dynamic nature of this market and its potential for continued growth and innovation.

The report delves into recent significant developments in the Nucleic Acid-Based Drugs Market, highlighting leading vendors and their innovative profiles. These include Alnylam Pharmaceuticals, Inc., Amgen Inc., Arcturus Therapeutics Holdings Inc., Arrowhead Pharmaceuticals, Inc., AstraZeneca PLC, Beam Therapeutics Inc., Biogen, Inc., BioMarin Pharmaceutical Inc., BioNTech SE, Bluebird Bio, Inc., CRISPR Therapeutics AG, CureVac N.V., Dynavax Technologies Corporation, Editas Medicine, Inc., Eli Lilly and Company, Evotec SE, F. Hoffmann-La Roche Ltd., Generation Bio Co., Gilead Sciences, Inc., GSK PLC, Intellia Therapeutics, Inc., Ionis Pharmaceuticals, Inc., Merck & Co., Inc., Moderna, Inc., Novartis AG, Novo Nordisk A/S, Orna Therapeutics, Inc., Pfizer Inc., ProQR Therapeutics N.V., Sangamo Therapeutics, Inc., Sanofi SA, Sarepta Therapeutics, Inc., Silence Therapeutics PLC, Stoke Therapeutics, Inc., Takeda Pharmaceutical Company Limited, Vertex Pharmaceuticals Incorporated, Voyager Therapeutics, Inc., and Wave Life Sciences Ltd.. Actionable Strategies for Market Leadership Advancement

Industry leaders are presented with a range of actionable recommendations to navigate the complexities of the nucleic acid-based drugs market. Foremost, sustaining competitive advantage requires continuous investment in research and development, with a particular emphasis on next-generation sequencing and novel therapeutic platforms. Embracing collaborative research models will enable the pooling of expertise and resources, thereby accelerating the transition from lab-scale studies to clinical applications.

Market leaders should also focus on integrating real-world evidence and data analytics to better understand patient outcomes and refine therapeutic pipelines. Strengthening relationships with regulatory bodies and aligning with evolving global standards can expedite market entry and mitigate compliance risks. Tailored strategies that emphasize precision medicine should aim to capture patient-specific nuances while also addressing broader clinical needs.

Given the dynamic nature of market segmentation, organizations would benefit from a flexible portfolio strategy that is responsive to shifts across drug types, molecule classifications, administration routes, therapeutic areas, and end-user segments. Leveraging digital transformation tools and advanced biomanufacturing capacity will be essential in optimizing supply chains and fostering efficiency. This strategic approach can not only enhance market share but also secure long-term sustainability in the face of evolving global health challenges.

In-depth Conclusion on Market Trends and Strategies

The comprehensive analysis of the nucleic acid-based drugs market reveals a landscape defined by rapid innovation, evolving regulatory practices, and growing clinical potential. Transformations in scientific discovery and technological integration have laid the foundation for novel therapeutic solutions that address previously unmet healthcare needs. The intersection of scientific excellence and strategic market segmentation has provided stakeholders with a nuanced understanding of market dynamics, underscoring the importance of tailored strategies in both clinical and commercial domains.

This executive summary reflects a synthesis of critical insights ranging from transformative market shifts and segmentation insights to regional and corporate strategies that are collectively shaping the future of nucleic acid-based therapeutics. As scientific advancements continue to redefine therapeutic paradigms, industry players are well-advised to pursue collaborative frameworks, invest in groundbreaking research, and adapt to the evolving landscape with agility. The compelling integration of regional insights and strategic corporate insights further signifies the promising trajectory of this vibrant market, positioning it as a key driver of future success in global health innovation.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of genetic disorders and chronic diseases drives the need for nucleic acid-based drugs
      • 5.1.1.2. Increasing government investments to advance nucleic acid drug manufacturing
    • 5.1.2. Restraints
      • 5.1.2.1. High manufacturing and formulation costs associated with nucleic acid-based drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Partnership and collaboration among biotech companies to enhance nucleic acid-based drugs
      • 5.1.3.2. Developing next-generation delivery systems to improve the bioavailability of nucleic acid drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Safety and delivery efficacy concerns of nucleic acid-based drugs
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Type: Usage of mRNA-based therapeutics due to transformative impact in vaccine development and rapid therapeutic responses during critical health crises
    • 5.2.2. Molecule Type: Widespread adoption of small molecule drugs due to their favorable properties in terms of manufacturing, administration, and cost-effectiveness
    • 5.2.3. Route of Administration: Prevalence of intramuscular injection due to its vital role in vaccine development
    • 5.2.4. Therapeutic Area: Utilization of nucleic acid-based drugs in oncology
    • 5.2.5. End-User: Widespread usage in academic & research institutes driven by need for advanced tools to unravel the intricacies of gene regulation and expression
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Nucleic Acid-Based Drugs Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Antisense Oligonucleotides
  • 6.3. DNA/RNA Aptamers
  • 6.4. mRNA-Based Therapeutics
  • 6.5. Nucleoside Analogs
  • 6.6. RNA Interference (RNAi) Therapeutics
    • 6.6.1. MicroRNA (MiRNA)
    • 6.6.2. Short Hairpin RNA (ShRNA)
    • 6.6.3. Short Interfering RNA (SiRNA)

7. Nucleic Acid-Based Drugs Market, by Molecule Type

  • 7.1. Introduction
  • 7.2. Large Molecule
  • 7.3. Small Molecule

8. Nucleic Acid-Based Drugs Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Inhalation
  • 8.3. Intramuscular
  • 8.4. Intravenous
  • 8.5. Oral
  • 8.6. Subcutaneous

9. Nucleic Acid-Based Drugs Market, by Therapeutic Area

  • 9.1. Introduction
  • 9.2. Cardiovascular Diseases
  • 9.3. Infectious Diseases
    • 9.3.1. Bacterial Infections
    • 9.3.2. Fungal Infections
    • 9.3.3. Viral Infections
  • 9.4. Metabolic Disorders
  • 9.5. Neurological Disorders
  • 9.6. Oncology
    • 9.6.1. Hematologic Malignancies
    • 9.6.2. Solid Tumors
  • 9.7. Rare Diseases

10. Nucleic Acid-Based Drugs Market, by End-User

  • 10.1. Introduction
  • 10.2. Academic & Research Institutes
  • 10.3. Contract Research Organizations
  • 10.4. Hospitals & Clinics
  • 10.5. Pharmaceutical & Biotechnology Companies

11. Americas Nucleic Acid-Based Drugs Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Nucleic Acid-Based Drugs Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Nucleic Acid-Based Drugs Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. SCG Cell Therapy collaborates with A*STAR BTI and NATi to fast-track RNA-based cell and gene therapy in Singapore
    • 14.3.2. FDA approves TRYNGOLZA, fueling a pipeline for nucleic acid therapies
    • 14.3.3. Singapore launches non-GMP NATi mRNA BioFoundry to enhance automated nucleic acid therapeutics research
    • 14.3.4. City Therapeutics secures USD 135 million Series A financing to revolutionize RNA interference therapies and advance next-generation RNAi engineering platform
    • 14.3.5. Evonik partners with KNAUER to expands its portfolio of biosolution
    • 14.3.6. GSK deepens its focus on nucleic acid-based treatments through the acquisition of Elsie Biotechnologies
    • 14.3.7. Aldevron and Acuitas Therapeutics join forces to accelerate next-generation cell and gene therapies
    • 14.3.8. UK invests GBP 4.5 million in advanced nucleic acid drug manufacturing
    • 14.3.9. Asahi Kasei Bioprocess and Axolabs forge a strategic Berlin partnership to build a 59,000 square foot cGMP facility for scalable oligonucleotide therapeutic production
    • 14.3.10. Evonik signs a license with the University of Mainz to commercialize a new class of PEG lipids for nucleic acid delivery
  • 14.4. Strategy Analysis & Recommendation
    • 14.4.1. Pfizer Inc.
    • 14.4.2. Novo Nordisk A/S
    • 14.4.3. Moderna, Inc.
    • 14.4.4. Ionis Pharmaceuticals, Inc.

Companies Mentioned

  • 1. Alnylam Pharmaceuticals, Inc.
  • 2. Amgen Inc.
  • 3. Arcturus Therapeutics Holdings Inc.
  • 4. Arrowhead Pharmaceuticals, Inc.
  • 5. AstraZeneca PLC
  • 6. Beam Therapeutics Inc.
  • 7. Biogen, Inc.
  • 8. BioMarin Pharmaceutical Inc.
  • 9. BioNTech SE
  • 10. Bluebird Bio, Inc.
  • 11. CRISPR Therapeutics AG
  • 12. CureVac N.V.
  • 13. Dynavax Technologies Corporation
  • 14. Editas Medicine, Inc.
  • 15. Eli Lilly and Company
  • 16. Evotec SE
  • 17. F. Hoffmann-La Roche Ltd.
  • 18. Generation Bio Co.
  • 19. Gilead Sciences, Inc.
  • 20. GSK PLC
  • 21. Intellia Therapeutics, Inc.
  • 22. Ionis Pharmaceuticals, Inc.
  • 23. Merck & Co., Inc.
  • 24. Moderna, Inc.
  • 25. Novartis AG
  • 26. Novo Nordisk A/S
  • 27. Orna Therapeutics, Inc.
  • 28. Pfizer Inc.
  • 29. ProQR Therapeutics N.V.
  • 30. Sangamo Therapeutics, Inc.
  • 31. Sanofi SA
  • 32. Sarepta Therapeutics, Inc.
  • 33. Silence Therapeutics PLC
  • 34. Stoke Therapeutics, Inc.
  • 35. Takeda Pharmaceutical Company Limited
  • 36. Vertex Pharmaceuticals Incorporated
  • 37. Voyager Therapeutics, Inc.
  • 38. Wave Life Sciences Ltd.

LIST OF FIGURES

  • FIGURE 1. NUCLEIC ACID-BASED DRUGS MARKET MULTI-CURRENCY
  • FIGURE 2. NUCLEIC ACID-BASED DRUGS MARKET MULTI-LANGUAGE
  • FIGURE 3. NUCLEIC ACID-BASED DRUGS MARKET RESEARCH PROCESS
  • FIGURE 4. NUCLEIC ACID-BASED DRUGS MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 19. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 21. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. NUCLEIC ACID-BASED DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 27. NUCLEIC ACID-BASED DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. NUCLEIC ACID-BASED DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. NUCLEIC ACID-BASED DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DNA/RNA APTAMERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MRNA-BASED THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEOSIDE ANALOGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MICRORNA (MIRNA), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SHORT INTERFERING RNA (SIRNA), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY LARGE MOLECULE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INHALATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY FUNGAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 59. ARGENTINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 60. ARGENTINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 61. ARGENTINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 66. BRAZIL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 67. BRAZIL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 68. BRAZIL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 69. BRAZIL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 70. CANADA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. CANADA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. CANADA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 75. CANADA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 76. CANADA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 77. CANADA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. MEXICO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. MEXICO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 80. MEXICO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. MEXICO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. MEXICO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 83. MEXICO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 84. MEXICO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 85. MEXICO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 88. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 90. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 91. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 92. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 93. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 104. AUSTRALIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 106. AUSTRALIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. AUSTRALIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 108. AUSTRALIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 109. AUSTRALIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 110. AUSTRALIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 111. AUSTRALIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. CHINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. CHINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 114. CHINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. CHINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 116. CHINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 117. CHINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 118. CHINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 119. CHINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. INDIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. INDIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 122. INDIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. INDIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 124. INDIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 125. INDIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 126. INDIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 127. INDIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. INDONESIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. INDONESIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 130. INDONESIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. INDONESIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 132. INDONESIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 133. INDONESIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 134. INDONESIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 135. INDONESIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. JAPAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. JAPAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 138. JAPAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. JAPAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 140. JAPAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 141. JAPAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 142. JAPAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 143. JAPAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. MALAYSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. MALAYSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 146. MALAYSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. MALAYSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 148. MALAYSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 149. MALAYSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 150. MALAYSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 151. MALAYSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 152. PHILIPPINES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. PHILIPPINES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 154. PHILIPPINES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. PHILIPPINES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 156. PHILIPPINES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 157. PHILIPPINES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 158. PHILIPPINES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 159. PHILIPPINES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 160. SINGAPORE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. SINGAPORE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 162. SINGAPORE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SINGAPORE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 164. SINGAPORE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 165. SINGAPORE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 166. SINGAPORE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 167. SINGAPORE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH KOREA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH KOREA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH KOREA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SOUTH KOREA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 172. SOUTH KOREA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 173. SOUTH KOREA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 174. SOUTH KOREA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 175. SOUTH KOREA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 176. TAIWAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. TAIWAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 178. TAIWAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. TAIWAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 180. TAIWAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 181. TAIWAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 182. TAIWAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 183. TAIWAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 184. THAILAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. THAILAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 186. THAILAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. THAILAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 188. THAILAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 189. THAILAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 190. THAILAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 191. THAILAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 192. VIETNAM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. VIETNAM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 194. VIETNAM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. VIETNAM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 196. VIETNAM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 197. VIETNAM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 198. VIETNAM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 199. VIETNAM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 209. DENMARK NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. DENMARK NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 211. DENMARK NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. DENMARK NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 213. DENMARK NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 214. DENMARK NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 215. DENMARK NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 216. DENMARK NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 217. EGYPT NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. EGYPT NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 219. EGYPT NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. EGYPT NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 221. EGYPT NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 222. EGYPT NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 223. EGYPT NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 224. EGYPT NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 225. FINLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. FINLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 227. FINLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. FINLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 229. FINLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 230. FINLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 231. FINLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 232. FINLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 233. FRANCE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. FRANCE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 235. FRANCE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 236. FRANCE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 237. FRANCE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 238. FRANCE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 239. FRANCE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 240. FRANCE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 241. GERMANY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 242. GERMANY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 243. GERMANY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 244. GERMANY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 245. GERMANY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 246. GERMANY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 247. GERMANY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 248. GERMANY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 249. ISRAEL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 250. ISRAEL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 251. ISRAEL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 252. ISRAEL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 253. ISRAEL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 254. ISRAEL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 255. ISRAEL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 256. ISRAEL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 257. ITALY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 258. ITALY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 259. ITALY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 260. ITALY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 261. ITALY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 262. ITALY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 263. ITALY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 264. ITALY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 265. NETHERLANDS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 266. NETHERLANDS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 267. NETHERLANDS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 268. NETHERLANDS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 269. NETHERLANDS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 270. NETHERLANDS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 271. NETHERLANDS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 272. NETHERLANDS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 273. NIGERIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 274. NIGERIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 275. NIGERIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 276. NIGERIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 277. NIGERIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 278. NIGERIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 279. NIGERIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 280. NIGERIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 281. NORWAY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 282. NORWAY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 283. NORWAY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 284. NORWAY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 285. NORWAY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 286. NORWAY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 287. NORWAY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 288. NORWAY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 289. POLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 290. POLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 291. POLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 292. POLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 293. POLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 294. POLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 295. POLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 296. POLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 297. QATAR NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 298. QATAR NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 299. QATAR NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 300. QATAR NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 301. QATAR NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 302. QATAR NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 303. QATAR NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 304. QATAR NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 305. RUSSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 306. RUSSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 307. RUSSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 308. RUSSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 309. RUSSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 310. RUSSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 311. RUSSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 312. RUSSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 313. SAUDI ARABIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 314. SAUDI ARABIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 315. SAUDI ARABIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 316. SAUDI ARABIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2